925252-30-8

Basic information

• Product Name: 2-(4-fluorophenyl)-N'-hydroxyethanimidamide
• Synonyms: 2-(4-fluorophenyl)-N'-hydroxyethanimidamide;(1Z)-2-(4-Fluorophenyl)-N'-hydroxyethanimidamide
• CAS NO: 925252-30-8
• Molecular Formula: C₈H₉FN₂O
• Molecular Weight: 168.17
• Mol File: 925252-30-8.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-fluorophenyl)-N'-hydroxyethanimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-fluorophenyl)-N'-hydroxyethanimidamide(925252-30-8)
• EPA Substance Registry System: 2-(4-fluorophenyl)-N'-hydroxyethanimidamide(925252-30-8)

Safety Data

• Hazardous Substances Data: 925252-30-8(Hazardous Substances Data)

Usage

Derivative

Ethanimidamide

Fluorine Substituent

Present on the phenyl ring

Pharmacological Properties

Anti-inflammatory and analgesic effects

Potential Use

Pain management and treatment of inflammatory conditions (e.g. arthritis)

Significance

Interesting subject for further research and potential pharmaceutical development

Upstream product

• 459-22-3 4-fluorophenylacetonitrile 

Downstream Products

• 221348-21-6 3-(4-fluoro-phenyl)-5-(4-methoxy-phenyl)-[1,2,4]oxadiazole 
• 200502-64-3 3-(4-Fluorobenzyl)-5-(4-N-tBoc-aminophenyl)-1,2,4-oxadiazole 
• 1036647-83-2 C₂₈H₂₆FN₅O₅ 
• 1036648-13-1 C₂₈H₂₄FN₅O₄ 
• 1235863-10-1 methyl-2-(4-fluorobenzyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate 
• 1289649-14-4 2-cyclopentyl-6-(3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl)-5-hydroxy-3-methylpyrimidin-4(3H)-one 
• 1289649-01-9 5-(benzyloxy)-2-cyclopentyl-6-(3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl)-3-methylpyrimidin-4(3H)-one 
• 1289648-97-0 5-(benzyloxy)-6-(3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl)-3-methyl-2-morpholinopyrimidin-4(3H)-one 
• 1289649-12-2 2-ethoxy-6-(3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl)-5-hydroxy-3-methylpyrimidin-4(3H)-one 
• 1289648-96-9 5-(benzyloxy)-2-ethoxy-6-(3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl)-3-methylpyrimidin-4(3H)-one 
• 1289649-13-3 6-(3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl)-5-hydroxy-3-methyl-2-morpholinopyrimidin-4(3H)-one 
• 957140-70-4 C₃₀H₂₅F₅N₄O₄ 

Relevant articles and documents

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments

Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1

Tryptophan metabolism through the kynurenine pathway is considered as a crucial mechanism in immune tolerance. Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism in the immune system and it is also considered as an important therapeutic target for the treatment of cancer and other diseases that are linked with kynurenine pathway. In this study, a series of nitrobenzofurazan derivatives of N′-hydroxybenzimidamides (1) and N′-hydroxy-2-phenylacetimidamides (2) were synthesized and their inhibitory activities against human IDO1 enzyme were tested using in-vitro and cellular enzyme activity assay. The optimization leads to the identification of potent compounds, 1d, 2i and 2k (IC50 = 39-80 nM), which are either competitive or uncompetitive inhibitors of IDO1 enzyme. These compounds also showed IDO1 inhibition potencies in the nanomolar range (IC50 = 50-71 nM) in MDA-MB-231 cells with no/negligible amount of cytotoxicity. The stronger selectivity of the potent compounds for IDO1 enzyme over tryptophan 2,3-dioxygenase (TDO) enzyme (312-1593-fold) also makes them very attractive for further immunotherapeutic applications.